Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece

被引：0
|
作者：
Tzanetakos, C. [1 ]
Kourlaba, G. [2 ]
Hatzikou, M. [3 ]
Antoniou, C. [4 ]
Ioannides, D. [5 ]
Lefaki, I. [6 ]
Petridis, A. [7 ]
Rigopoulos, D. [8 ]
Roussaki-Schulze, V. [9 ]
Sotiriadis, D. [10 ]
Maniadakis, N. [1 ]
机构：
[1] Natl Sch Publ Hlth, Hlth Serv Org & Management, Athens, Greece
[2] Aghia Sophia Childrens Hosp, Collaborat Ctr Clin Epidemiol & Outcomes Res CLEO, Athens, Greece
[3] Novartis Hellas SACI SA, Athens, Greece
[4] Univ Athens, Hosp Venereol Dermatol Dis A Syggros, Athens, Greece
[5] Aristoteleio Univ Thessaloniki, Hosp Skin & Venereal Dis, Thessaloniki, Greece
[6] Hosp Skin & Venereal Dis, Dermatol Clin, Thessaloniki, Greece
[7] Hosp Venereol Dermatol Dis A Syggros, Dermatol Clin, Athens, Greece
[8] Univ Athens, Attikon Univ Hosp Athens, Athens, Greece
[9] Univ Thessaly, Univ Hosp Larissa, Larisa, Greece
[10] Aristoteleio Univ Thessaloniki, Gen Hosp Thessaloniki PAPAGEORGIOU, Thessaloniki, Greece
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
cost-effectiveness; plaque psoriasis; secukinumab;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P125
引用
收藏
页码：61 / 62
页数：2
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF USTEKINUMAB VERSUS ETANERCEPT IN SEVERE PLAQUE PSORIASIS PATIENTS: A CANADIAN PERSPECTIVE
    Brazier, N.
    Pan, F.
    Shear, N.
    Jivraj, F.
    Schenkel, B.
    Brown, R.
    VALUE IN HEALTH, 2009, 12 (07) : A457 - A457
  • [22] COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB COMPA RED WITH ETANERCEPT FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COSTA RICA
    Obando, C. A.
    Desanvicente-Celis, Z.
    Herrera, J. A.
    Moreira, M.
    De Castro, J.
    VALUE IN HEALTH, 2014, 17 (07) : A607 - A607
  • [23] IMPACT OF DOSE ESCALATION ON AVERAGE COST AND COST-EFFECTIVENESS OF ANTI-TNF AND USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN SWEDEN
    Ziegler, F.
    Apol, E.
    Egeberg, A.
    VALUE IN HEALTH, 2018, 21 : S450 - S450
  • [24] COST-EFFECTIVENESS OF SECUKINUMAB IN MODERATE TO SEVERE PSORIASIS COMPARED WITH OTHER BIOLOGICS IN GERMANY
    Graham, C. N.
    McBride, D.
    Miles, L.
    Gilloteau, I
    O'Neill, C. B.
    Neidhardt, K.
    Augustin, M.
    VALUE IN HEALTH, 2017, 20 (05) : A157 - A157
  • [25] COST PER RESPONDER OF SECUKINUMAB COMPARED TO OTHER BIOLOGICS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS IN BRAZIL
    Suzuki, C.
    Lopes, N.
    Tozato, C.
    Gilloteau, I
    Graham, C. N.
    VALUE IN HEALTH, 2018, 21 : S240 - S240
  • [26] COST-EFFECTIVENESS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A803 - A803
  • [27] Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry
    Egeberg, A.
    Iversen, L.
    Gniadecki, R.
    Hvid, L.
    Dam, T. N.
    Bryld, L. E.
    Skov, L.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (07) : 1183 - 1187
  • [28] Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis
    Scanlon, James V.
    Exter, Benjamin P.
    Steinberg, Michael
    Jarvis, Courtney I.
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (09) : 1456 - 1465
  • [29] A COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE AND SEVERE PSORIASIS IN MEXICO
    Vargas-Valencia, J.
    Sotelo-Guzman, M.
    Mould-Quevedo, J. F.
    Mucino-Ortega, E.
    Galindo-Suarez, R. M.
    VALUE IN HEALTH, 2011, 14 (03) : A55 - A55
  • [30] Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis
    Martin, Silas
    Feldman, Steven R.
    Augustin, Matthias
    Szapary, Philippe
    Schenkel, Brad
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2011, 22 (03) : 138 - 143
12345